Hospital News

Viroblock Launches New Face Mask

Views: 1.1K

Viroblock Respiratory Mask

Viroblock SA, a Swiss start-up, today presented new data at ICPIC 2013 in Geneva, showing that their face-mask containing proprietary novel cholesterol depletion technology traps and kills over 99.9995% of H1N1 flu viruses (swine flu), 99.999% of H5N1 flu viruses (avian flu) and 99.997% human corona viruses on pass through air. Aimed at helping protect people from these respiratory pathogens, the mask is up to one hundred times more effective than a similar mask without Viroblock technology. The company will now start direct sales in Switzerland and is looking for distributors in other countries.

Aerobiology tests for face-masks simulate real life situations, in which the user is exposed to viruses coming in. The mask helps prevent transmission from and to the person wearing the mask. commented Dr Thierry Pelet, CSO at Viroblock. The stringent testing demonstrates the efficacy and speed at which the cholesterol depletion technology works.

Aerobiology tests, carried out in high security laboratories, create a mist of viruses on the outside of the mask, a pump is used to draw air and viruses through the mask, and finally testing for live virus occurs on the inside of the mask.

We believe that our protective face-mask can help protect healthcare, agriculture and security workers effectively, with added advantages of comfort of wear and easy identification, said Dr Jamie Paterson, CEO of Viroblock.

Viroblock SA is a CTI Certified Swiss start-up located in Geneva, Switzerland. Founded in 2006 and supported mainly by Swiss investors, the company is focused on developing a unique anti-viral technology based on cholesterol depletion. Viroblocks first product is an anti-viral face mask and other air filtration products are planned.

 

Latest News

To Top